Acquisition of INBRIJA (levodopa inhalation powder) and (F)AMPYRA (fampridine) expands specialty neurology portfolio Lays groundwork for Parkinson’s disease franchise and anchor in multiple sclerosis ...
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA ® (levodopa inhalation powder) in six ...
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be ...
Alert FDA OKs Inhaled Levodopa (Inbrija) for Parkinson's 'Off' Episodes Levodopa inhalation powder aims to fill an unmet need for roughly 40% of patients with Parkinson's who experience off periods ...
Chance Pharmaceuticals Co. Ltd. acquired greater China rights to Inbrija (levodopa inhalation powder), used to manage Parkinson’s disease (PD), from Acorda Therapeutics Inc. in a deal worth as much as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results